A Randomized, Double-Blind, Placebo-Controlled, Single Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Adult Male Japanese and White Subjects

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Single Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Adult Male Japanese and White Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Jul 2017

At a glance

  • Drugs Elenbecestat (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Eisai Inc
  • Most Recent Events

    • 20 Jul 2017 Results assessing the effects of Elenbecestat on QTc intervals in healthy subjects from a 4-way crossover study and a PK bridging study (NCT02222324 and NCT02207790) presented at the Alzheimer's Association International Conference 2017
    • 12 Dec 2016 According to Eisai media release, results were presented as a poster at the 9th Clinical Trials on Alzheimer's Disease (CTAD) meeting.
    • 12 Dec 2016 Results published in the Eisai Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top